Users Coming Off Weight-Loss Medications Regain Weight Four Times Faster Compared to Those on Conventional Diets

New research reveals that individuals who discontinue new weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.

Research printed in a prominent medical journal demonstrates that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.

"People buying these medications should be cognizant of the danger of quick weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.

That rate of regain implies a reversion to starting weight within about a year and a half.

Comparing Therapies

The research, which reviewed dozens of trials involving thousands of patients, contrasted the effects of these new drugs with older methods.

Researchers note that individuals who shed pounds through diet and exercise typically experience a slower creep back—approximately 0.1 kg a month—after stopping.

The Reason for the Quick Regain

Experts suggest the way of the jabs explains the amplified rebound.

The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.

"Sustained high doses of the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural GLP-1, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.

"Withdrawal of this hormone supplement results in hunger is uncontrolled, making excessive eating far more likely."

A Chronic Disease?

The NHS suggest the jabs for individuals with weight-linked health risks, alongside prescribed lifestyle changes.

Professionals say that, considering the significant potential of weight regain, the treatment might need to be long-term.

This perspective is supported by pharmaceutical companies, who note that the findings "highlight the long-term nature of excess weight," similar to managing diseases like diabetes.

User Experiences

Individuals who have discontinued the jabs describe a sudden resurgence of appetite.

"It felt as if something flipping and you become starving," said one woman.

The struggle is exacerbated if users have not established sustainable dietary or behavioural modifications during treatment.

Widespread Adoption

Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.

• Adoption is higher among females compared to males.
• The middle-aged age group shows the greatest level of interest.
• Many access the drugs through private healthcare rather than public health services.

Finally, clinicians caution that while these medications are potent tools for weight loss, they are not a magic cure and maintained weight loss relies on ongoing behavioural management.